HUTCHMED (China) Limited (HCM.L)

262,00 -7,00 (-2,60%) Al cierre: 04:35PM BST

HUTCHMED (China) Limited

Cheung Kong Center
48th floor 2 Queen's Road Central
Hong Kong
Hong Kong
852 2121 8200
https://www.hutch-med.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1970

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Wei-Guo Su B.Sc., Ph.D.	CEO, Chief Scientific Officer & Executive Director	1,85M	N/A	1958
Mr. Chig Fung Cheng BEc, CA	CFO & Executive Director	725,82k	N/A	1967
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E	Company Secretary & Non-Executive Director	N/A	N/A	1952
Ms. Yiling Cui	Executive VP & Head of Operations	N/A	N/A	N/A
David Ng	Head of Investor Relations & Capital Strategies	N/A	N/A	N/A
Mr. Charles George Rupert Nixon	Group General Counsel	N/A	N/A	1970
Mr. Kin Hung Lee M.B.A.	Senior Vice President of Corporate Management & Communications	N/A	N/A	1977
Ms. Selina Zhang	Senior Vice President of Global Human Resources	N/A	N/A	N/A
Dr. Qingmei Wang Ph.D.	Senior Vice President of Business Development & Strategic Alliances	N/A	N/A	1963
Mr. Hong Chen	Executive VP & Chief Commercial Officer- China	N/A	N/A	1970

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en GBp.

Descripción

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Gobierno corporativo

El ISS Governance QualityScore de HUTCHMED (China) Limited, a día 1 de septiembre de 2024, es 2. Las puntuaciones base son Auditoría: 2; Tablero: 1; Derechos de los accionistas: 9; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.